Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Botulinum Toxin A Delivery via Iontophoresis vs Injection for Palmar Hyperhidrosis
NCT01262339Phase 3Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2010
- Primary completion
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of botulinum toxin type A in palmar hyperhidrosis (PH), sponsored by University of Wisconsin–Madison. Primary endpoint: Evaluate the Efficacy of Botulinum Toxin A (BTX-A) in the Treatment of Primary Palmar Hyperhidrosis Delivered Via Iontophoresis at 26 weeks. Started Nov 2010; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
palmar hyperhidrosis (PH)
Beyond the preview
Go deeper on NCT01262339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262339.